International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud, and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- A multidisciplinary team from Cleveland Clinic, RIKEN and IBM advanced to the finals of the 2026 ACM Gordon Bell Prize for simulating the largest biologically meaningful molecules ever modeled with quantum computers, reaching 12,635 atoms. - The work unites quantum and classical computing in a quantum-centric supercomputing framework, using up to 94 qubits and nearly 6,000 quantum operations alongside the Fugaku and Miyabi-G supercomputers. - The team scaled its method roughly 40-fold and achieved a 210-fold improvement in accuracy within a year, while improving computed binding energies relevant to predicting drug–protein interactions. - The 2026 Gordon Bell Prize winner will be announced at SC26 in Chicago, Nov. 15–20, 2026.
- QC Ware and IonQ demonstrated a hybrid quantum-classical chemistry workflow that modeled the heme active site of cytochrome P450nor within 0.5 kcal/mol (~4%) of classical benchmarks, clearing the 1 kcal/mol chemical-accuracy threshold. - The workflow paired QC Ware's Promethium platform with IonQ's Forte trapped-ion quantum computer via Amazon Braket, achieving more than double the accuracy of the standard classical mean-field method. - Accurately predicting binding energy at iron sites in enzymes like P450nor could help pharmaceutical researchers better rank drug candidates and identify metabolic risks earlier in the R&D pipeline. - The hardware-agnostic demonstration shows Promethium's hybrid approach is not tied to a single quantum architecture, following a prior demonstration on IBM's 156-qubit Heron superconducting processor.
- A novel AI model developed through the Cleveland Clinic-IBM Discovery Accelerator identifies hidden sleep patterns linked to heart disease, cognitive decline, and death from routine polysomnography data. - Patients in the highest-risk group had twice the five-year mortality risk compared to the lowest-risk group, a distinction not captured by the standard apnea-hypopnea index. - The model performed well for both men and women, addressing a known limitation of the apnea-hypopnea index which historically performs better in men. - Findings, published in Nature Communications and validated in a nationwide cohort, suggest routine medical tests may contain substantially more physiological information than current clinical practice extracts.
- IBM CEO Arvind Krishna projects quantum computing will begin contributing measurable revenue and profit by 2028 or 2029, with total value reaching one trillion dollars by the end of the 2030s. - New research with Algorithmiq demonstrates quantum advantage, showing quantum computers can perform tasks beyond the reach of classical computers, with applications in drug discovery, materials science, and batteries. - IBM plans a standalone quantum chip foundry backed by $2 billion in combined investment from the U.S. CHIPS program and IBM to strengthen domestic quantum processor manufacturing. - Krishna addressed investor concerns following IBM's stock decline, noting approximately 40% of delayed enterprise deals had already closed within three to four weeks, signaling deferrals rather than cancellations.
- Cleveland Clinic and IBM hosted the third annual Cleveland Discovery and Innovation Forum, highlighting progress in applying quantum computing and AI to healthcare and life sciences research. - The Discovery Accelerator partnership has supported more than 50 projects and modeled a protein of over 12,000 atoms, the largest structure known to be simulated on a quantum computer. - Cleveland Clinic launched the 2026 Global Quantum + AI Challenge focused on unlocking undruggable targets through quantum simulation of allosteric signal propagation. - The challenge will award $200,000 across five enterprise challenges, with $40,000 allocated per challenge, to bridge quantum theory and real-world impact.
- Qubit Pharmaceuticals demonstrated quantum algorithms can achieve exponential speedups for irreversible processes like chemical reactions and protein folding, overturning previous theoretical limits. - The company established a practical roadmap for quantum utility in drug discovery by 2028, successfully demonstrating protein-pocket hydration-site prediction on 123-qubit quantum processors. - Microsoft and Algorithmiq are collaborating to develop fault-tolerant quantum chemistry algorithms that achieve "chemical accuracy" for molecular simulations in drug discovery. - These advances represent significant progress toward making quantum computing genuinely useful for pharmaceutical research and materials science applications.
- Cardiovascular diseases remain the leading cause of death globally with 19 million deaths in 2020, despite advances in drug development, highlighting the need for precision medicine approaches that address disease heterogeneity at molecular, cellular, and patient levels. - Systems biology approaches integrating multiomics data, network medicine, and artificial intelligence are enabling identification of novel biomarkers and drug targets while improving patient stratification and therapeutic development timelines. - New therapeutic platforms including RNA-targeted interventions, computational drug discovery, and cell-type-specific delivery methods offer promise for overcoming traditional druggability barriers and reducing development costs from current 9.1-year averages.
- Moderna has formed a strategic partnership with IBM to leverage quantum computing and generative artificial intelligence for advancing mRNA medicine discovery and development. - The collaboration aims to deepen understanding of mRNA molecular behavior, refine molecular structures, and improve lipid nanoparticle delivery systems used in mRNA therapeutics. - Moderna joins a growing group of pharmaceutical companies including Biogen and Bayer that are embracing quantum computing technologies to accelerate drug discovery processes. - The partnership positions Moderna to harness quantum computing's potential to investigate larger molecules and solve previously intractable problems in mRNA research.
- The second annual London Biotechnology Show (#LBS25) builds on the success of its inaugural edition, which attracted over 3,000 attendees from 1,500 companies and featured 70+ sponsors and exhibitors. - This year's expanded event features a 4,000 square meter floor plan showcasing cutting-edge products and services from leading companies including Discovery Park, Merck, Microsoft, and AstraZeneca. - The show introduces a Hosted Buyer Programme offering pre-arranged one-to-one meetings to facilitate strategic partnerships and business growth opportunities. - An enhanced conference program will feature speakers from major organizations including Novo Nordisk, Pfizer, Bayer Pharmaceuticals, and the Medicines and Healthcare products Regulatory Agency discussing gene editing, regenerative medicine, and digital health innovations.
- Advanced AI algorithms and improved data integration capabilities are poised to revolutionize drug discovery through in silico testing and molecular compound simulation, significantly accelerating pharmaceutical development. - Machine learning systems are expected to enhance diagnostic accuracy in medical imaging beyond human capabilities, particularly in radiology and pathology for precise tumor detection and treatment matching. - AI-powered platforms will streamline clinical trial recruitment and regulatory compliance, while Large Language Models will revolutionize medical documentation processes across the pharmaceutical industry.
